{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:55Z","timestamp":1760239855773,"version":"build-2065373602"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.hoc.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T02:02:15Z","timestamp":1622167335000},"page":"739-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"35","author":[{"given":"Wei","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.hoc.2021.04.001_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"5015","key":"10.1016\/j.hoc.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tcb.2011.10.006","article-title":"Deconstructing p53 transcriptional networks in tumor suppression","volume":"22","author":"Bieging","year":"2012","journal-title":"Trends Cell Biol"},{"issue":"6303","key":"10.1016\/j.hoc.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/348747a0","article-title":"Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome","volume":"348","author":"Srivastava","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.04.001_bib7","first-page":"564","article-title":"p53 modifications: exquisite decorations of the powerful guardian","volume":"11","author":"Liu","year":"2019","journal-title":"J\u00a0Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"a026054","DOI":"10.1101\/cshperspect.a026054","article-title":"Transcriptional regulation by wild-type and cancer-related mutant forms of p53","volume":"7","author":"Pfister","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/j.hoc.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1073\/pnas.052713099","article-title":"Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function","volume":"99","author":"de Vries","year":"2002","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.hoc.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.hoc.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1200\/JCO.2011.34.7872","article-title":"Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia","volume":"29","author":"Trbusek","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41375-020-0723-2","article-title":"Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial","volume":"34","author":"Blakemore","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","article-title":"Survival of Del17p CLL depends on genomic complexity and somatic mutation","volume":"23","author":"Yu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7574","key":"10.1016\/j.hoc.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.hoc.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/gm451","article-title":"Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics","volume":"5","author":"Landau","year":"2013","journal-title":"Genome Med"},{"key":"10.1016\/j.hoc.2021.04.001_bib20","article-title":"Role of mutant p53 in the progression of chronic lymphocytic leukemia","volume":"134","author":"Janani Ravikrishnan","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hoc.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2021.04.001_bib23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-141014","article-title":"Ibrutinib induces durable remissions in treatment-na\u00efve CLL patients with 17p deletion\/TP53 mutations: five year follow-up from a phase 2 study","volume":"136","author":"Mariela Sivina","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2021.04.001_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-134431","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials","volume":"136","author":"Allan","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"10232","key":"10.1016\/j.hoc.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2021.04.001_bib33","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion","author":"Tam","year":"2020","journal-title":"Haematologica"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib34","first-page":"11","article-title":"PhD10 and Alessandra Tedeschi, MD11\u2217","volume":"136","author":"Jennifer","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2021.04.001_bib36","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.04.001_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"34","key":"10.1016\/j.hoc.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2021.04.001_bib41","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2021.04.001_bib42","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2021.04.001_bib43","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.hoc.2021.04.001_bib44","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134783","article-title":"Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment na\u00efve (TN) and relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): results from the phase 3\u00a0Unity-CLL Study","volume":"136","author":"Gribben","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2021.04.001_bib47","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.hoc.2021.04.001_bib48","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2021.04.001_bib49","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2021.04.001_bib50","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib51","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.hoc.2021.04.001_bib52","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2021.04.001_bib53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2021.04.001_bib54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.hoc.2021.04.001_bib55","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib56","first-page":"15","article-title":"High clonal complexity of resistance mechanisms occurring at progression after single-agent targeted therapy strategies in chronic lymphocytic leukemia","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2021.04.001_bib57","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2021.04.001_bib58","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2013-10-534271","article-title":"Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness","volume":"123","author":"Messina","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2021.04.001_bib59","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2021.04.001_bib60","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A\u00a0single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.04.001_bib64","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2021.04.001_bib65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.hoc.2021.04.001_bib66","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2021.04.001_bib67","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2021.04.001_bib68","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.hoc.2021.04.001_bib69","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"De Paoli","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"10.1016\/j.hoc.2021.04.001_bib70","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2021.04.001_bib71","doi-asserted-by":"crossref","first-page":"E2911","DOI":"10.1073\/pnas.1702564114","article-title":"Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia","volume":"114","author":"Fabbri","year":"2017","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2021.04.001_bib73","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.hoc.2021.04.001_bib74","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2021.04.001_bib75","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.hoc.2021.04.001_bib76","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2021.04.001_bib77","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2021.04.001_bib78","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.04.001_bib79","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.04.001_bib80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-137061","article-title":"Large-scale proteomics identifies distinct signatures for Richter syndrome and de novo diffuse large B-cell lymphoma: a French study from the Filo Group","volume":"136","author":"Romain Morizot","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2021.04.001_bib82","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.04.001_bib83","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"suppl","key":"10.1016\/j.hoc.2021.04.001_bib84","article-title":"Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter\u2019s syndrome (RS)","volume":"36","author":"Wang","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.04.001_bib85","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib86","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2021.04.001_bib87","doi-asserted-by":"crossref","first-page":"594841","DOI":"10.3389\/fimmu.2020.594841","article-title":"Microenvironment remodeling and subsequent clinical implications in diffuse large B-cell histologic variant of Richter syndrome","volume":"11","author":"Auge","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2021.04.001_bib88","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.hoc.2021.04.001_bib89","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2021.04.001_bib90","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Jennifer Woyach","year":"2019","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib91","first-page":"35","article-title":"LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: results from the phase 1\/2 BRUIN study","volume":"136","author":"Anthony","year":"2020","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-134314","article-title":"LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenstr\u00f6m's macroglobulinemia, and other non-Hodgkin lymphomas: results from the phase 1\/2 BRUIN study","volume":"136","author":"Michael Wang","year":"2020","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib93","first-page":"39","article-title":"Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"136","author":"William","year":"2020","journal-title":"Blood"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib94","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-140491","article-title":"Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients","volume":"136","author":"Tanya Siddiqi","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2021.04.001_bib95","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T\u00a0cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2021.04.001_bib96","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and efficacy of CD19-CAR T\u00a0cells in Richter\u2019s transformation after targeted therapy for chronic lymphocytic leukemia","volume":"136","author":"Ohad Benjamini","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2021.04.001_bib98","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.hoc.2021.04.001_bib99","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.hoc.2021.04.001_bib100","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2021.04.001_bib101","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib102","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2021.04.001_bib103","article-title":"A\u00a0phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation","volume":"132","author":"Nitin Jain","year":"2018","journal-title":"Blood"},{"issue":"52","key":"10.1016\/j.hoc.2021.04.001_bib104","article-title":"Phase I\/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with REL\/REF CLL and Richter's transformation","volume":"37","author":"Nasta","year":"2019","journal-title":"Hematological Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib105","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2021.04.001_bib106","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1016\/j.hoc.2021.04.001_bib107","article-title":"Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia","volume":"36","author":"Hampel","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.hoc.2021.04.001_bib108","article-title":"A\u00a0multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter\u2019s syndrome","volume":"38","author":"Matthew Steven Davids","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supple 1","key":"10.1016\/j.hoc.2021.04.001_bib109","first-page":"21","article-title":"A\u00a0once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed\/refractory Richter\u2019s transformation and de novo diffuse large B-cell lymphoma","volume":"136","author":"Anthony","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2021.04.001_bib110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14728222.2020.1832465","article-title":"Targeting p53 in chronic lymphocytic leukemia","volume":"24","author":"Moia","year":"2020","journal-title":"Expert Opin Ther Targets"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:17:08Z","timestamp":1760185028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0889858821000447"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.04.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}